E Lopez1, S Yoshimatsu2, A Querri1, L Coprada1, J Bermejo3, M R Paulino4, A Medina5, A M C Garfin6, A Ohkado7. 1. Research Institute of Tuberculosis/Japan Anti-Tuberculosis Association (RIT/JATA) Philippines, Manila, The Philippines. 2. RIT/JATA, Tokyo, Japan ; Department of Paediatrics, National Hospital Organisation Minami-Kyoto Hospital, Kyoto, Japan. 3. Manila Health, Department, Manila, The Philippines. 4. Quezon City Health Department, Quezon City, The Philippines. 5. National Capital Region Office, Mandaluyong, The Philippines. 6. Disease Prevention and Control Bureau, Department of Health, Manila, The Philippines. 7. Research Institute of Tuberculosis/Japan Anti-Tuberculosis Association (RIT/JATA) Philippines, Manila, The Philippines ; RIT/JATA, Tokyo, Japan.
Abstract
Setting: Socio-economically underprivileged urban areas in the Philippines. Objectives: To identify gaps in the referral pathway of presumptive drug-resistant tuberculosis (DR-TB) patients from initial consultation until initiation of treatment. Design: A retrospective study in which a masterlist of presumptive multidrug-resistant TB (MDR-TB) patients registered in 18 DOTS facilities in Tondo, Manila and Payatas, Quezon City, from October 2012 to September 2013, was analysed and reviewed. Results: Among 378 presumptive DR-TB patients identified and listed in the masterlist, 97% (368/378) were referred, of whom 90% (333/368) were screened at an MDR-TB treatment centre. Of the 368 patients, 35 (9.5%) were not screened, mainly due to loss to follow-up. Among those screened, 86.4% (288/333) were recommended for anti-tuberculosis treatment, of whom 98.2% (283/288) initiated treatment. The time between sample collection and examination was significantly longer at the laboratories of non-government organisations (NGOs) than at local government units (LGUs) (1 day vs. 0 day; P < 0.001). The time to the release of smear examination results to patients was significantly shorter at the NGOs than at the LGUs (4 days vs. 6 days; P = 0.009). Conclusion: The development of the presumptive MDR-TB masterlist facilitated tracking of patients for diagnosis and treatment. The NGOs should reduce delays in diagnosis and the LGUs should intensify patient follow-up to ensure early initiation of treatment.
Setting: Socio-economically underprivileged urban areas in the Philippines. Objectives: To identify gaps in the referral pathway of presumptive drug-resistant tuberculosis (DR-TB) patients from initial consultation until initiation of treatment. Design: A retrospective study in which a masterlist of presumptive multidrug-resistant TB (MDR-TB) patients registered in 18 DOTS facilities in Tondo, Manila and Payatas, Quezon City, from October 2012 to September 2013, was analysed and reviewed. Results: Among 378 presumptive DR-TBpatients identified and listed in the masterlist, 97% (368/378) were referred, of whom 90% (333/368) were screened at an MDR-TB treatment centre. Of the 368 patients, 35 (9.5%) were not screened, mainly due to loss to follow-up. Among those screened, 86.4% (288/333) were recommended for anti-tuberculosis treatment, of whom 98.2% (283/288) initiated treatment. The time between sample collection and examination was significantly longer at the laboratories of non-government organisations (NGOs) than at local government units (LGUs) (1 day vs. 0 day; P < 0.001). The time to the release of smear examination results to patients was significantly shorter at the NGOs than at the LGUs (4 days vs. 6 days; P = 0.009). Conclusion: The development of the presumptive MDR-TB masterlist facilitated tracking of patients for diagnosis and treatment. The NGOs should reduce delays in diagnosis and the LGUs should intensify patient follow-up to ensure early initiation of treatment.
Authors: Paul K Drain; Emily P Hyle; Farzad Noubary; Kenneth A Freedberg; Douglas Wilson; William R Bishai; William Rodriguez; Ingrid V Bassett Journal: Lancet Infect Dis Date: 2013-12-10 Impact factor: 25.071